|
Apr 17
|
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
|
|
Apr 17
|
Should You Continue to Hold Veracyte Stock in Your Portfolio?
|
|
Apr 16
|
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
|
|
Apr 15
|
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
|
|
Apr 14
|
Here's Why Veracyte (VCYT) is a Strong Growth Stock
|
|
Apr 11
|
Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain?
|
|
Mar 13
|
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally?
|
|
Mar 10
|
Veracyte (VCYT) Surged on Reporting Strong Earnings
|
|
Mar 4
|
Veracyte Full Year 2024 Earnings: EPS Misses Expectations
|
|
Mar 3
|
Veracyte's (NASDAQ:VCYT) Performance Is Even Better Than Its Earnings Suggest
|
|
Feb 27
|
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom
|
|
Feb 24
|
Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates
|
|
Feb 24
|
Veracyte: Q4 Earnings Snapshot
|
|
Feb 24
|
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 21
|
Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
|
|
Feb 20
|
High Growth Tech Stocks To Watch In February 2025
|
|
Feb 14
|
Schrodinger Stock Scores IBD Rating Upgrade
|
|
Feb 14
|
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
|
|
Feb 13
|
Best Momentum Stocks to Buy for February 13th
|
|
Feb 11
|
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
|